安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- OPZELURA® (ruxolitinib) | Healthcare Professionals
See info for healthcare professionals about OPZELURA® across all uses Learn about the patient support program See Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA®
- Nonsegmental Vitiligo Treatment | OPZELURA® (ruxolitinib) HCP
OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Limitations of Use: Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended
- Dosing | Atopic Dermatitis | OPZELURA® (ruxolitinib) HCP
View information for healthcare providers about OPZELURA® dosing for patients with mild to moderate atopic dermatitis See the Full Prescribing Information, including Boxed Warning, and Medication Guide
- Topical Atopic Dermatitis Treatment | OPZELURA® (ruxolitinib) HCP
Learn about treatment with OPZELURA®, including mechanism of action, clinical trials and results, dosing, and helpful resources See the Full Prescribing Information, including Boxed Warning, and Medication Guide
- Mechanism of Action | Atopic Dermatitis | OPZELURA® (ruxolitinib) HCP
View information on the mechanism of action of OPZELURA® for people with mild to moderate atopic dermatitis See the Full Prescribing Information, including Boxed Warning, and Medication Guide
- Mechanism of Action | OPZELURA® (ruxolitinib) HCP
View info for healthcare providers about the OPZELURA® mechanism of action See the Full Prescribing Information, including Boxed Warning, and Medication Guide
- Dosing | Nonsegmental Vitiligo | OPZELURA® (ruxolitinib) HCP
View info about OPZELURA® dosing for patients with nonsegmental vitiligo See the Full Prescribing Information, including Boxed Warning, and Medication Guide
- Cost Savings | Atopic Dermatitis | OPZELURA® (ruxolitinib) HCP
OPZELURA is indicated for the topical and chronic treatment of mild to moderate atopic dermatitis in adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable : Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as
|
|
|